Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CytoSorbents Corporation
Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
While US regulators have ramped up the number of authorizations they’ve granted to companies on an emergency basis in response to the COVID-19 crisis, they really kicked things into high gear in just the past few days. On 10 April the agency issued a record number of EUAs in response to the pandemic.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.
- Medical Devices
- Other Names / Subsidiaries
- MedaSorb Technologies Corporation, CytoSorbents Medical UK Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.